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consider mycobacterial infections and inquire about
recent pedicures in patients with apparent lower-
extremity furunculosis. Tissue cultures and sensitiv-
ity studies should be performed to guide treatment,
given the widespread antibiotic resistance of myco-
bacteria species. Early recognition of the organisms
and institution of appropriate therapy are critical.
Physicians and the public need to be educated about
the possibility of infections following pedicures, and
physicians should inquire about pedicures when
faced with nonhealing furunculosis of the lower legs.
Public health measures should be explored to pro-
tect against such infections given the recent increase
in popularity of the nail care industry.
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Photodynamic therapy (PDT) is a treatment based on the accumulation of a photosensitizer in the target
cells and their selective destruction by irradiation with visible light. In the past 10 years, several patients
with cutaneous T cell lymphoma have been successfully treated. The use of PDT in cutaneous B cell
lymphoma has not been reported to date. We report the successful PDT treatment of 3 patients with early
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ndolent primary cutaneous B-cell lymphomas
(CBCL), that is, follicular center and marginal
zone lymphoma according to the European
Organization for Research and Treatment of Cancer1
(EORTC) and the recent consensus World Health
OrganizationeEORTC classification,2 are character-
ized by mostly local or regional extension and very
good prognosis (rare extracutaneous spread, despite
relatively frequent cutaneous relapses, and 5-year
survival rate [95%). Both types are highly res-
ponsive to local radiotherapy (RT).2 Small, isolated
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Brief reports 525lesions can be surgically excised, with or without
additional RT.2 The treatment with multiple-agent
chemotherapy should be restricted, at presentation,
to the definitely occasional patients with dissemi-
nated lesions, to those refractory to or with multiple
relapses after RT.2 Other treatment modalities, such
as intralesional cisplatin-epinephrine gel3 and anti-
CD20 monoclonal antibody,2 has been reported as
being of possible help in specific circumstances.
Photodynamic therapy (PDT) is a treatment mo-
dality based on the administration of a photosensitiz-
ing compound that accumulates in the target cells,
followed by selective irradiation of the lesion with
visible light. The combination of two individually
nontoxic elements, drug and light, is responsible for
PDT-mediated response (reviewed in Kalka, Merk,
and Mukhtar4), presumably via apoptotic cell death
as a major mechanism5 with minimal or no necrotic
changes. The most widely used photosensitizer is
aminolevulinic acid (ALA), first proposed in 1978
by Dougherty et al6 for the treatment of mycosis
fungoides (MF). To date, other case series of MF
patients (both in plaque and tumor stages) and 2
patients with CD301 cutaneous T-cell lymphoma
(CTCL) successfully treated with PDT have been
reported.7-15
To date, no reports are available concerning
the use of systemic or local PDT in the treatment of
CBCL. We report herein about the successful ALA-
PDT treatment of 3 patients with early CBCL.
PATIENTS AND METHODS
Three patients with CBCL, whose data are sum-
marized in Table I, were treated with PDT. The
diagnosis was established by routine histopath-
ology and immunophenotyping according to the
WHO-EORTC classification.2 In two patients (1 and
2; Table I), skin lesions (thin plaques) had never
been treated. In patient 3, the treated lesion had
relapsed 6 months after complete remission obtained
by orthovolt RT.
ALA 20% (oil-in-water emulsion) was applied
topically to the lesion and to adjacent skin under
an occlusive and light-shielding dressing for 4 hours
in patients 1 and 3. In patient 2, the methyl ester of
Abbreviations used:
ALA: aminolevulinic acid
CBCL: cutaneous B-cell lymphoma
CTCL: cutaneous T-cell lymphoma




RT: radiotherapyALA (Metvix; Photocure, Oslo, Norway and Galderma,
Paris, France) was applied. The red fluorescence of
porphyrins was visualized with Wood’s light before
treatment. Fluorescence was seen in all cases. The
ALA-treated areas were then exposed to incoherent
light using a light-emitting diode lamp (Aktilite PDT,
model CL128; Photocure ASA, Oslo, Norway) at a
wavelength of 630 nm and a light dose of 37 J/cm2
with light intensity of 70 to 100 mW/cm2. It illumi-
nates areas from 80 to 180 mm at a distance from 50 to
80 mm. The patients were examined after 1 week,
and, depending on the clinical results, the treatment
was repeated (patient 3). Four-millimeter punch
biopsy specimens were taken before treatment
and after clinical remission. Clinical evaluation was
performed monthly after PDT, with an 8- to
24-month follow-up.
RESULTS
The treatment was well tolerated by all patients
without local anesthetics. The results are summarized
inTable I. All patientsunderwent complete remission,
defined as clinical and histologic complete remission,
with a maximum of two treatment sessions at 1-week
intervals. Two patients (1 and 2) were in complete
remission after 1 week from the first (and only) PDT
session. Patient 3 underwent complete remission after
1 week from the second PDT session (Fig 1).
DISCUSSION
PDT consists of the application of a photosensitiz-
ing agent and irradiation with noncoherent light
Fig 1. Patient 3. A, Plaque on right flank, relapsing
immediately outside border of previous radiotherapy field.
B, One week after the second (and last) PDT session.
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Patient no. Age (y)/sex Disease/stage Previous tx PDT sessions Photosensitizer Results Follow-up (mo)
1 62/F CBCL (FCL) None 1 ALA CR 17
2 38/F CBCL (MZL) None 1 Metvix CR 8
3 56/M CBCL (MZL) RT 2 ALA CR 24
ALA, Aminolevulinic acid 20%, oil-in-water emulsion; CBCL, cutaneous B-cell lymphoma; CR, complete response; FCL, follicle center
lymphoma; Metvix, methyl ester of ALA; MZL, marginal zone lymphoma; PDT, photodynamic therapy; RT, orthovolt radiotherapy (20 Gy);
tx, therapy.sources. Photoactivation of photosensitizing porphy-
rins, which selectively accumulate in tumor cells,
induces healing with minimal or nonecrotic changes.
PDT has been successfully used in CTCL (MF and
CD301 CTCL).7-12
We treated 3 patients with early CBCL, with
complete remission achieved in all 3 after a maxi-
mum of two PDT sessions. The successful use of
ALA-PDT in indolent CBCL, to our knowledge re-
ported herein for the first time, suggests a possible
role of PDT in the treatment of localized, thin
plaques as an alternative to local RT, which has to
be considered the treatment of choice. Additional
studies on larger series will hopefully contribute to
clarify this issue.
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